Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nina Dobrić
Observed names:
N. Dobric,
N. Dobrić,
Nina Dobric
Institution:
Medical University of Graz
Observed institution:
Medical University of Graz
ORCID:
0009-0001-1742-9271
Observed ORCID:
0009-0001-1742-9271
OpenAlex ID:
A5026906320
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria
2026
·
N. Dobrić
, S.O. Hasenleithner
, et al.
·
ESMO Open
·
3
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2− breast cancer: insights and implications
2025
·
Eva Valentina Klocker
, Nina Dobrić
, et al.
·
npj Breast Cancer
·
2
PDF
Abstract P5-06-02: Comparison of lobular vs NST hormone receptor-positive metastatic breast cancer patients in early lines of treatment via comprehensive genomic profiling and whole-genome sequencing of circulating tumor DNA
2025
·
Eva Valentina Klocker
, Nina Dobric
, et al.
·
Clinical Cancer Research
·
1
54P Comparison of ctDNA profiles in lobular vs NST hormone receptor-positive metastatic breast cancer patients in early lines of treatment
2024
·
E.V.V. Klocker
, N. Dobrić
, et al.
·
ESMO Open
·
1
PDF
Abstract PS1-12-20: Circulating tumor DNA profiling of patients with early-line advanced luminal breast cancer
2026
·
N. Dobrić
, S. O. Hasenleithner
, et al.
·
Clinical Cancer Research
511P Pathogenic ESR1 alterations and co-alterations in HR+/HER2- advanced breast cancer
2025
·
N. Dobric
, C. Suppan
, et al.
·
Annals of Oncology
Circulating tumor DNA profiling of patients with metastatic luminal HER2-low and HER2-0 breast cancer via next-generation sequencing.
2025
·
Nina Dobrić
, Nadia Dandachi
, et al.
·
Journal of Clinical Oncology
PDF
High-sensitivity detection and broad genomic profiling in HR+/HER2- breast cancer: Final comparative results using targeted single-gene and broad-panel sequencing assays
2024
·
Marija Balic
, Eva Valentina Klocker
, et al.
·
The Journal of Liquid Biopsy
491P Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
2023
·
N. Dobrić
, N. Dandachi
, et al.
·
Annals of Oncology
PDF
2261P A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2- breast cancer patients
2023
·
N. Dandachi
, R. Graf
, et al.
·
Annals of Oncology
PDF
Prirođene srčane grješke u pasa: prevalencija, dijagnostika i liečenje
2019
·
N. Dobrić
Show more works
View as search
Works count:
11
Citation count:
7
H-index:
2
I10-index:
Year
Topic
Type